Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Regulus Therapeutics Company Profile (NASDAQ:RGLS)

Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $14.76 (130.99% upside)

Current Analysts' Coverage Summary for Regulus Therapeutics (NASDAQ:RGLS)
Show:
DateFirmActionRatingPrice TargetDetailsShare
6/17/2014ZacksUpgradeUnderperform -> Neutral$7.80ViewTweet This Rating  Share This Rating on StockTwits
5/13/2014Brinson PatrickInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
5/9/2014BMO Capital MarketsBoost Price Target$15.00 -> $18.00ViewTweet This Rating  Share This Rating on StockTwits
4/15/2014TheStreetDowngradeHold -> SellViewTweet This Rating  Share This Rating on StockTwits
2/28/2014Needham & Company LLCBoost Price Target$14.00ViewTweet This Rating  Share This Rating on StockTwits
2/7/2014WedbushBoost Price Target$17.00 -> $19.00ViewTweet This Rating  Share This Rating on StockTwits
11/14/2013Cowen and CompanyReiterated RatingOutperformViewTweet This Rating  Share This Rating on StockTwits
10/30/2013FBR & Co.Initiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
10/30/2013FBR Capital MarketsInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
8/14/2013Lazard Capital MarketsBoost Price TargetBuy$14.00 -> $15.00ViewTweet This Rating  Share This Rating on StockTwits
11/1/2012Lazard LtdInitiated CoverageBuy$14.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 8/1/2012 forward)